Frailty and sarcopenia

Abstract

Sarcopenia and frailty are geriatric syndromes that are frequently underdiagnosed and bidirectionally linked to type 2 diabetes (T2D) in older adults, occurring at a markedly higher prevalence than in people without diabetes. Chronic hyperglycemia, subclinical inflammation, and microvascular complications accelerate skeletal muscle deterioration, while the resulting loss of muscle mass and strength further impairs metabolic control, creating a self-reinforcing negative feedback loop1. Diabetes is also an independent risk factor for frailty, a syndrome defined by reduced physiological reserve in the face of acute stressors such as hospitalization, infection, or hypoglycemia2.

Early detection can be achieved in routine office visits using simple, low-cost tools that require no specialized technology or referral: the SARC-F questionnaire, 4-meter gait speed, and handgrip strength allow at-risk patients to be identified, reserving bioimpedance or dual-energy X-ray absorptiometry for diagnostic confirmation3. Timely recognition is essential, since both syndromes are associated with a higher risk of falls, severe hypoglycemia, hospitalization, disability, and mortality, independent of glycemic control. Annual screening is advised for all patients aged 65 years and older, along with reassessment after any hospitalization or acute decompensation.

Diabetes treatment should be individualized according to the degree of frailty. In frail patients, HbA1c targets should be relaxed, low-hypoglycemia-risk agents prioritized over sulfonylureas and complex insulin regimens, and overtreatment avoided, with therapeutic deintensification considered whenever risk outweighs benefit4. Resistance exercise remains the non-pharmacological intervention with the strongest evidence base and should be paired with adequate protein intake (1.0–1.5 g/kg/day) and correction of vitamin D deficiency.

Incorporating sarcopenia and frailty screening into routine diabetes follow-up — through brief questions and simple functional measures — allows functional decline to be anticipated and treatment adjusted in time, improving quality of life, preserving independence, and reducing preventable complications in this vulnerable population.